ALDH1 is an immunohistochemical diagnostic marker for solitary fibrous tumours and haemangiopericytomas of the meninges emerging from gene profiling study
Open Access
- 9 May 2013
- journal article
- research article
- Published by Springer Science and Business Media LLC in Acta Neuropathologica Communications
- Vol. 1 (1), 10
- https://doi.org/10.1186/2051-5960-1-10
Abstract
Solitary Fibrous Tumours (SFT) and haemangiopericytomas (HPC) are rare meningeal tumours that have to be distinguished from meningiomas and more rarely from synovial sarcomas. We recently found that ALDH1A1 was overexpressed in SFT and HPC as compared to soft tissue sarcomas. Using whole-genome DNA microarrays, we defined the gene expression profiles of 16 SFT/HPC (9 HPC and 7 SFT). Expression profiles were compared to publicly available expression profiles of additional SFT or HPC, meningiomas and synovial sarcomas. We also performed an immunohistochemical (IHC) study with anti-ALDH1 and anti-CD34 antibodies on Tissue Micro-Arrays including 38 SFT (25 meningeal and 13 extrameningeal), 55 meningeal haemangiopericytomas (24 grade II, 31 grade III), 163 meningiomas (86 grade I, 62 grade II, 15 grade III) and 98 genetically confirmed synovial sarcomas. ALDH1A1 gene was overexpressed in SFT/HPC, as compared to meningiomas and synovial sarcomas. These findings were confirmed at the protein level. 84% of the SFT and 85.4% of the HPC were positive with anti-ALDH1 antibody, while only 7.1% of synovial sarcomas and 1.2% of meningiomas showed consistent expression. Positivity was usually more diffuse in SFT/HPC compared to other tumours with more than 50% of tumour cells immunostained in 32% of SFT and 50.8% of HPC. ALDH1 was a sensitive and specific marker for the diagnosis of SFT (SE = 84%, SP = 98.8%) and HPC (SE = 84.5%, SP = 98.7%) of the meninges. In association with CD34, ALDH1 expression had a specificity and positive predictive value of 100%. We show that ALDH1, a stem cell marker, is an accurate diagnostic marker for SFT and HPC, which improves the diagnostic value of CD34. ALDH1 could also be a new therapeutic target for these tumours which are not sensitive to conventional chemotherapy.Keywords
This publication has 49 references indexed in Scilit:
- Possible involvement of stem-like populations with elevated ALDH1 in sarcomas for chemotherapeutic drug resistanceOncology Reports, 2010
- Genomic Landscape of MeningiomasBrain Pathology, 2010
- IGF2 over‐expression in solitary fibrous tumours is independent of anatomical location and is related to loss of imprintingThe Journal of Pathology, 2010
- Molecular characterization of the response to chemotherapy in conventional osteosarcomas: Predictive value of HSD17B10 and IFITM2International Journal of Cancer, 2009
- Specific Genes Expressed in Association with Progesterone Receptors in MeningiomaCancer Research, 2008
- Detection of SS18-SSX fusion transcripts in formalin-fixed paraffin-embedded neoplasms: analysis of conventional RT-PCR, qRT-PCR and dual color FISH as diagnostic tools for synovial sarcomaLaboratory Investigation, 2007
- Inhibition of aldehyde dehydrogenase and retinoid signaling induces the expansion of human hematopoietic stem cellsProceedings of the National Academy of Sciences of the United States of America, 2006
- Determination of Stromal Signatures in Breast CarcinomaPLoS Biology, 2005
- Exploration, normalization, and summaries of high density oligonucleotide array probe level dataBiostatistics, 2003
- Expression of CD34 in endothelial cells, hematopoietic progenitors and nervous cells in fetal and adult mouse tissuesEuropean Journal of Immunology, 1995